Pulmonary sequestration is a type of bronchopulmonary malformation defined as an isolated portion of lung tissue with systemic arterial supply and no bronchial communication. Carbohydrate antigen 19-9 (CA19-9) has been used for diagnosis and follow-up of gastrointestinal tumors. The current study presents a rare case of intralobar pulmonary sequestration associated with the marked elevation of CA19-9.
Background
Pulmonary sequestration is a rare congenital abnormality characterized by the presence of lung tissues that are not attached to the pulmonary arterial blood architecture but receive blood supply from an anomalous systemic artery 1 . As a result, sequestrated lung tissues fail to function in or contribute to respiration. In 1946, Pryce first dubbed the condition "pulmonary sequestration," which can be divided into two types according to the morphology: intralobar and extralobar 2 . Intralobar pulmonary sequestration is typically located in the posterior basilar segment of the lower lobe sharing a common visceral pleura. It accounts for 75 percent of all sequestrations and is usually diagnosed in early childhood with symptoms of recurrent infections, hemoptysis, or pleural effusion. The extralobar variety accounts for 25% of cases.
The anomalous tissue is isolated from normal lung tissue with its own pleural envelope and may be located in the pericardium, in the mediastinum, as well as below the diaphragm 3 .
Carbohydrate antigen 19-9 (CA19-9) was first identified by Koprowski in 1979 4 and is an important and well recognized tumor marker for pancreatobiliary and gastrointestinal tract cancer. In addition, recent clinical investigations have revealed that CA19-9 levels can also be elevated in other gastrointestinal tract disorders such as benign pancreatic, liver and biliary tract diseases 5, 6 , and in respiratory diseases such as idiopathic interstitial pneumonia, collagen disease-associated pulmonary fibrosis, diffuse panbronchiolitis, and lung cancer. Therefore, the CA19-9 is not a specific marker for gastrointestinal, pancreatic and biliary malignancies 7, 8 .
There has been a growing interest in investigating the relationship between pulmonary sequestration and elevated CA19-9 since Shiota et al. first reported a case of increased levels of CA19-9 in pulmonary sequestration in and elevated CA19-9. We present a new case of pulmonary sequestration and elevated CA19-9 and have reviewed all reports related to pulmonary sequestration and elevated serum CA19-9 levels since it was first reported in the literature.
Case Report Presentation
A 39-year-old woman was referred to our hospital with complaints of fatigue and weakness. Physical examination was normal except for yellowing of the sclera and skin. Laboratory examinations on admission showed significant increases in serum alanine aminotransferase
bilirubin (94 μmol! L) and CA19-9 (3,051.1 μ! mL) ( Table   1 ). An initial diagnosis of acute icteric hepatitis was made. However, the etiologies of hepatitis such as viral infection, alcohol and hepato-toxic drugs intake, nonalco- There were no significant events in the postoperative course. Ten days after the excision of the tissue, the serum CA19-9 levels dramatically declined to 756 U! mL and returned to the normal value after 6 months ( Fig. 2) . 
Discussion
Our patient presented with acute hepatitis and an increased CA19-9 level. Significant elevation of serum CA19-9 has been reported in several publications in connection with acute liver failure 10 , chronic viral hepatitis 11 and liver cirrhosis 12 . However, in our patient, after one month of treatment for acute hepatitis, the liver enzymes recovered but the serum CA19-9 level was even higher (5,031.5 u! mL), indicating that the elevated CA19-9 level was not related to the acute hepatitis. There have been no reports of any association between acute hepatitis and pulmonary sequestration, and our case did not support any link between acute hepatitis and pulmonary sequestration, either.
An association between pulmonary sequestration and elevated serum CA19-9 levels has been reported by several Japanese investigators since it was first identified by Shiota in 1988. In order to better understand our case, we conducted electronic searches of pulmonary sequestration and elevated serum CA19-9 levels in medical databases worldwide. We found 15 clinical cases, which are summarized in Table 2 . These reported cases included 11 females and 5 males with an average age of 40 years (20 64 years), suggesting higher morbidity in women than in men. Moreover, the majority (80%) of the cases were of intralobar sequestration, which reflects the higher occurrence of intralobar sequestration than extralobar sequestration. The average serum CA19-9 levels in these reported cases was 1,060.7 U! mL (range: 73.8 U! mL to 3,051.1 U! mL), making our case the highest reported serum CA19-9 levels. Steinberg et al. claim that higher levels of serum CA19-9 (>1,000 U! mL) indicate gastrointestinal tract cancer, especially with a specificity of more than 99% for pancreatobiliary cancer 13 . However, no malignan- cies were detected in these reported cases after various examinations, although one patient was misdiagnosed with lung cancer 14 . In the majority of the reported cases, immunohistochemical staining of CA19-9 in resected tissue was also performed, demonstrating local CA19-9
in the bronchial and alveolar epithelia of sequestrated Moreover, confirmation of infection with aspergillosis has been reported in three patients 22 24 , leading us to suspect that the elevated CA19-9 level in our patient was due to aspergillosis infection. Alternatively, CA19-9 could have first synthesized and accumulated in the lesion and then been transferred into the bloodstream through the mucosa of the cyst walls, leading to a high level of CA19-9.
Pulmonary sequestration is uncommon, with an estimated incidence in 0.15% to 1.7% of patients worldwide 25 . Despite its rarity, these lesions are considered to be of clinical importance. Standard treatment for pulmonary sequestration is resection, which is often accomplished by video-assisted thoracoscopic surgery. Among 16 reported cases, 13 had an average healing time of 2.8 months and 9 reported that the serum CA19-9 levels rapidly decreased to normal range surgery within 1 or 2 months of surgery. However, our patient took 6 months to recover to a normal level, which might have been because of the higher initial levels of CA19-9.
To the best of our knowledge, this is the first report of an elevated serum CA19-9 level in a patient with acute hepatitis and pulmonary sequestration. The reported cases of pulmonary sequestration and elevated CA19-9 levels indicate that CA19-9 is not a specific marker of digestive tract cancers, although it could be a diagnostic marker of pulmonary sequestration. However, not all patients with pulmonary sequestration have elevated serum CA19-9 levels. An understanding of the mechanism of CA19-9 elevation in pulmonary sequestration will clarify the correlation between CA19-9 and pulmonary sequestration. In conclusion, we have reviewed the literature and reported on a patient with pulmonary sequestration and an elevated levels of CA19-9, a diagnostic marker for gastroenterologists and pulmonologists. Elevated serum CA19-9 might be a helpful adjunctive marker to identify pulmonary sequestration when CT-scans do not reveal anomalous systemic vessels.
